Novartis Financials

Market Capitalization CHF173.38 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	16.94
Forward PE	14.03
Price to Sales TTM	CHF3.47
Price to Book MRQ	CHF4.00
Enterprise to Revenue	3.85
Enterprise to EBITDA	9.17

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	35.25%
Operating Margin	33.47%
Return on Assets TTM	10.59%
Return on Equity TTM	28.79%

Income Statement

Revenue TTM	CHF44,588,928,686
Revenue per Share TTM	CHF24.54
Quarterly Revenue Growth	8.90%
Gross Profit TTM	CHF34,188,000,000
EBITDA	CHF19,709,000,000
Net Income to Common TTM	CHF10,500,809,014
Diluted EPS TTM	CHF5.12
Quarterly Earnings Growth YoY	81.10%

Balance Sheet

Total Cash MRQ	CHF12,366,864,901
Total Cash per Share MRQ	CHF6.93
Total Debt MRQ	CHF
Total Debt to Equity MRQ	74.03
Current Ratio MRQ	1.11
Book Value per Share MRQ	CHF21.67

Cash Flow

Operating Cash Flow TTM	CHF14,261,492,901
Levered Free Cash Flow TTM	CHF5,067,593,173

NOVN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	1,999,270,016
Float Shares	1,907,863,407
Avg 10 Volume	4,158,549
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	4.11%
% Held by Institutions	38.97%

Stock Price Summary

Beta	0.51
Fifty Two Week Low	CHF83.63
Fifty Two Week High	CHF102.72
Fifty Two Week Change	-2.94%
Day 50 MA	CHF93.62
Day 200 MA	CHF94.02

Dividends and Splits

Forward Annual Dividend Rate	CHF13.20
Forward Annual Dividend Yield	14.62%
Trailing Annual Dividend Rate	CHF3.30
Trailing Annual Dividend Yield	3.66%
Payout Ratio	65.52%
Dividend Date	2024-03-11
Ex Dividend Date	2024-03-07
Last Split Factor
Last Split Date	2023-10-04